DexteraAI uses AI-enabled surgical video analysis to objectively characterize subretinal therapeutic delivery in gene and cell therapy trials.
We identify procedural phenotypes that may help explain complications, delivery consistency, imaging findings, and favorable or unfavorable clinical outcomes.
Initial focus: subretinal therapeutic trials in wet AMD, dry AMD / geographic atrophy, and retinal gene and cell therapy programs requiring surgical delivery.
DexteraAI converts routine surgical video into objective procedural biomarkers, helping gene and cell therapy sponsors understand whether variation in surgical delivery contributes to procedural and clinical outcomes.
Clinical outcomes may reflect not only the therapy, dose, and patient—but also how the therapy was delivered. That procedural variability is rarely quantified.
Learn more →DexteraAI converts surgical video into objective procedural biomarkers of instrument-tip behavior, including Precision, Instability, Drift, and Tremor.
Learn more →Retinal gene and cell therapy programs requiring subretinal delivery — focused on the critical delivery maneuver in wet AMD, GA, and inherited retinal disease.
Learn more →DexteraAI's initial focus is retinal gene and cell therapy programs requiring subretinal delivery. These trials involve high-value biologic products, technically demanding surgical administration, and narrow regulatory and adoption pathways because established intravitreal therapies already exist for major retinal diseases.
The initial use case is not broad surgical video review. It is focused analysis of the critical subretinal delivery maneuver.
Four applications spanning pre-pivotal analysis through post-market surgeon quality assurance.
Determine whether a complication or unexpected result occurred with a procedural phenotype different from comparable uncomplicated cases.
Evaluate whether favorable cases share reproducible delivery characteristics.
Test whether procedural biomarkers are associated with safety, imaging, delivery, or clinical outcomes.
Use validated procedural findings to support training, device selection, workflow refinement, and prospective trial design.
Whether you are planning a pivotal trial or interpreting a completed one, DexteraAI can quantify subretinal delivery performance and evaluate it against your sponsor-defined procedural and clinical endpoints.